Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Transition complete

Executive Summary

Former Warner-Lambert Global Pharmaceutical President Anthony Wild, PhD, has formed a specialty pharmaceutical investment fund, MedPointe Capital Partners. Wild was one of the top-ranking Warner-Lambert executives on the transition team following the Pfizer merger. Wild has also joined the Allergan board of directors, replacing former SmithKline Beecham Chairman Henry Wendt

You may also be interested in...



MedPointe CEO succession

MedPointe Chairman and CEO Anthony Wild will retire effective May 1. He is succeeded by President Paul Edick, who joined MedPointe from Pharmacia in 2002 as president of the Wallace Pharmaceuticals division. Wild co-founded MedPointe in 2000 after leaving an executive position with Warner-Lambert when it was acquired by Pfizer (1"The Pink Sheet" Aug. 7, 2000, p. 32). Wild will now serve as non-executive chairman of the board, allowing him to support the leadership transition and assist in identifying new growth initiatives...

MedPointe CEO succession

MedPointe Chairman and CEO Anthony Wild will retire effective May 1. He is succeeded by President Paul Edick, who joined MedPointe from Pharmacia in 2002 as president of the Wallace Pharmaceuticals division. Wild co-founded MedPointe in 2000 after leaving an executive position with Warner-Lambert when it was acquired by Pfizer (1"The Pink Sheet" Aug. 7, 2000, p. 32). Wild will now serve as non-executive chairman of the board, allowing him to support the leadership transition and assist in identifying new growth initiatives...

Soma Tablet Particles Show No Adverse Health Effects, MedPointe Tells FDA

MedPointe expects to address FDA's Soma manufacturing concerns with a final report showing no adverse health effects from black specks found on carisoprodol tablets

Related Content

UsernamePublicRestriction

Register

PS036481

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel